Latest Pharma and Biotech News
Pharmaceutical
6 March 2026 Servier, a French independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026.
Today's issue
Refine search
Biotechnology
Significant research news last week included United Therapeutics releasing positive Phase III data on its ralinepag for pulmonary arterial hypertension (PAH). French biotech OSE Immunotherapeutics announced a strategic refocusing of its pipeline. On the deal making front, Moderna reached a $2.25 billion settlement with Genevant and Arbutus on authorized use of CNP technology. The week ended with the Director of the US Center for Biologics Evaluation and Research, Dr Vinay Prasad, saying he would be leaving the post in April. 8 March 2026
Biotechnology
After the close of stock markets on Friday, the Wall street Journal (WSJ) reported (here) that Director of the Center for Biologics Evaluation and Research (CBER), Dr Vinay Prasad, will leave the agency in April. 7 March 2026
Pharmaceutical
Earlier this past week, the US Food and Drug Administration held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs to the American consumer. 7 March 2026
Pharmaceutical
Hangzhou Sciwind Biosciences, a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. 6 March 2026
Pharmaceutical
Servier, a French independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026. 6 March 2026
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Biotechnology
Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for relapsed or refractory multiple myeloma (RRMM) patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. 6 March 2026
Pharmaceutical
Seattle-based Nautilus Biotechnology, a specialist in single-molecule proteome analysis, has announced the appointment of Amber Faust as vice president of sales. 6 March 2026
Biotechnology
Cambridge, USA-based precision allosteric therapeutics biotech Atavistik Bio has announced the closing of a $40 million extension to its Series B financing from new investor RA Capital Management, bringing the total round proceeds to $160 million. 6 March 2026
Pharmaceutical
US drugmaker Vertex Pharmaceuticals today announced data from a Phase IV study of Journavx (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. 6 March 2026
Pharmaceutical
Swiss pharma Roche reported positive Phase II results for its investigational amylin analog petrelintide, showing meaningful weight loss and a placebo-like tolerability profile in people living with overweight and obesity. 6 March 2026
Pharmaceutical
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization following the divestment of opioid dependence treatment Zubsolv (buprenorphine/naloxone). 6 March 2026
Pharmaceutical
The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a draft guidance document outlining how clinical trials should be conducted during public health emergencies (PHEs). The guidance, now open for stakeholder consultation, is intended for sponsors and all parties involved in the design and conduct of clinical trials in the European Union, The European Medicines (EMA) announced late Thursday. 6 March 2026
Pharmaceutical
I've worked with pharmaceutical companies for years, and one pattern keeps repeating: the most significant environmental, health, and safety (EHS) risks are rarely dramatic. They sit in routine practices, steadily increasing cost and exposure without drawing much attention. 5 March 2026
Pharmaceutical
Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study evaluating HLP004 as a potential treatment for adults with moderate-to-severe generalized anxiety disorder (GAD) who remained symptomatic despite ongoing SoC antidepressant therapy, including selective serotonin reuptake inhibitors and related agents. 5 March 2026
Pharmaceutical
Swiss drugmaker Roche has released findings from a global survey suggesting that the unpredictability of diabetes continues to shape everyday life for many patients, limiting spontaneity and adding a persistent mental burden. 5 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
Germany’s Merck KGaA reported broadly stable full-year 2025 results, with modest top-line pressure from currency headwinds but continued profitability, while investors focused on a softer outlook for 2026. 5 March 2026
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
French pharma Sanofi has agreed to license the experimental drug rovadicitinib from China’s Sino Biopharmaceutical, paying $135 million upfront for exclusive development and commercialization rights outside China. 5 March 2026
All news
Biotechnology
Significant research news last week included United Therapeutics releasing positive Phase III data on its ralinepag for pulmonary arterial hypertension (PAH). French biotech OSE Immunotherapeutics announced a strategic refocusing of its pipeline. On the deal making front, Moderna reached a $2.25 billion settlement with Genevant and Arbutus on authorized use of CNP technology. The week ended with the Director of the US Center for Biologics Evaluation and Research, Dr Vinay Prasad, saying he would be leaving the post in April. 8 March 2026
Biotechnology
After the close of stock markets on Friday, the Wall street Journal (WSJ) reported (here) that Director of the Center for Biologics Evaluation and Research (CBER), Dr Vinay Prasad, will leave the agency in April. 7 March 2026
Pharmaceutical
Earlier this past week, the US Food and Drug Administration held a meeting with several states to discuss the section 804 importation program (SIP), which allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs to the American consumer. 7 March 2026
Pharmaceutical
Hangzhou Sciwind Biosciences, a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. 6 March 2026
Pharmaceutical
Servier, a French independent international pharmaceutical group governed by a foundation, today announced that it has entered into a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash. The transaction remains subject to customary closing conditions and is expected to close in the second quarter of 2026. 6 March 2026
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Biotechnology
Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for relapsed or refractory multiple myeloma (RRMM) patients who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. 6 March 2026
Pharmaceutical
Seattle-based Nautilus Biotechnology, a specialist in single-molecule proteome analysis, has announced the appointment of Amber Faust as vice president of sales. 6 March 2026
Biotechnology
Cambridge, USA-based precision allosteric therapeutics biotech Atavistik Bio has announced the closing of a $40 million extension to its Series B financing from new investor RA Capital Management, bringing the total round proceeds to $160 million. 6 March 2026
Pharmaceutical
US drugmaker Vertex Pharmaceuticals today announced data from a Phase IV study of Journavx (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. 6 March 2026
Pharmaceutical
Swiss pharma Roche reported positive Phase II results for its investigational amylin analog petrelintide, showing meaningful weight loss and a placebo-like tolerability profile in people living with overweight and obesity. 6 March 2026
Pharmaceutical
Swedish specialty pharma Orexo is reorganizing its management team as it pivots away from direct US commercialization following the divestment of opioid dependence treatment Zubsolv (buprenorphine/naloxone). 6 March 2026
Pharmaceutical
The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a draft guidance document outlining how clinical trials should be conducted during public health emergencies (PHEs). The guidance, now open for stakeholder consultation, is intended for sponsors and all parties involved in the design and conduct of clinical trials in the European Union, The European Medicines (EMA) announced late Thursday. 6 March 2026
Pharmaceutical
I've worked with pharmaceutical companies for years, and one pattern keeps repeating: the most significant environmental, health, and safety (EHS) risks are rarely dramatic. They sit in routine practices, steadily increasing cost and exposure without drawing much attention. 5 March 2026
Pharmaceutical
Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study evaluating HLP004 as a potential treatment for adults with moderate-to-severe generalized anxiety disorder (GAD) who remained symptomatic despite ongoing SoC antidepressant therapy, including selective serotonin reuptake inhibitors and related agents. 5 March 2026
Pharmaceutical
Swiss drugmaker Roche has released findings from a global survey suggesting that the unpredictability of diabetes continues to shape everyday life for many patients, limiting spontaneity and adding a persistent mental burden. 5 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
Germany’s Merck KGaA reported broadly stable full-year 2025 results, with modest top-line pressure from currency headwinds but continued profitability, while investors focused on a softer outlook for 2026. 5 March 2026
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
French pharma Sanofi has agreed to license the experimental drug rovadicitinib from China’s Sino Biopharmaceutical, paying $135 million upfront for exclusive development and commercialization rights outside China. 5 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A Swedish specialty pharmaceutical company focused on drug delivery technologies and treatments for substance use disorders, mental health conditions and emergency medicines. Orexo combines proprietary formulation platforms with established active pharmaceutical ingredients to develop improved medicines and rescue therapies.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze